Safety and Immunogenicity of Live Attenuated Influenza H5N2

NCT01841918 ↗

Phase 2 Completed 150 enrolled Mahidol University The Government Pharmaceutical Organization · collab World Health Organization · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate immune response and safety of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, Thailand in healthy Thais.

Timeline

Start: 2013-01
Primary completion: 2013-05
Completion: 2013-06

Publications

Pitisuttithum P, Boonnak K, Chamnanchanunt S, Puthavathana P, Luvira V, Lerdsamran H, Kaewkungwal J, Lawpoolsri S, Thanachartwet V, Silachamroon U, Masamae W, Schuetz A, Wirachwong P, Thirapakpoomanunt S, Rudenko L, Sparrow E, Friede M, Kieny MP. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017 Aug;17(8):833-842. doi: 10.1016/S1473-3099(17)30240-2. Epub 2017 May 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	A/17/turkey/Turkey/05/133 (H5N2)	Vaccine	0.25 ml	Intranasal

Safety and Immunogenicity of Live Attenuated Influenza H5N2

Summary

Timeline

Publications

Drugs

Indications